Health and Healthcare
Major Pharma Short Sellers Couldn't Make Up Their Minds Before Failed Trump Health Care Vote
Published:
Last Updated:
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The Trump administration has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It has yet to be seen how much headway the White House can actually make with these reforms, especially after the House of Representatives failed to vote on Trump’s repeal of Obamacare.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
Short interest in Pfizer Inc. (NYSE: PFE) fell sharply to 89.05 million shares from the previous 110.37 million. Its shares were last seen at $34.00, within a 52-week trading range of $29.41 to $37.39.
The number of Merck & Co. Inc. (NYSE: MRK) shares short increased slightly to 17.37 million from 17.23 million in the previous period. Its shares were trading at $63.18, in a 52-week range of $52.44 to $66.80.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest rose to 21.87 million shares, compared to the previous level of 20.51 million. Shares were trading at $32.76, in a 52-week range of $31.90 to $58.16.
The sharp fall in Bristol-Myers Squibb Co. (NYSE: BMY) short interest was to 35.06 million shares, from the previous reading of 47.39 million. Shares were trading at $55.89, within a 52-week range of $46.01 to $77.12.
The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 35.74 million, compared to the previous 29.95 million. The stock was trading at $65.62, in a 52-week range of $55.06 to $68.12.
Eli Lilly and Co.’s (NYSE: LLY) short interest decreased to 9.35 million shares from the previous 12.15 million. The stock was trading at $84.18. The 52-week range is $64.18 to $86.14.
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.